Thus, the dosage sensitivity of PMP22 disrupts myelin homeostasis in opposite ways, leading to different clinical phenotypes [4]. These case series explore the variability in clinical presentations and disease progression of CMT and HNPP, emphasizing the diagnostic challenges and the crucial role of genetic testing in confirming the diagnosis. Here, PMP22 is linked to hereditary neuropathy with liability to pressure palsies.